The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC.
The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.
Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.
Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.
Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.
Allyson Ocean, MD, discusses the development of novel therapeutic regimens in pancreatic cancer.
Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.
Investigators are looking into a combination of immunotherapy agents for patients with unresectable hepatocellular carcinoma, for whom there are limited treatment options in the first line.
Aiwu Ruth He, MD, PhD, discusses the future of precision medicine in gastrointestinal cancers.
Lenvatinib (Lenvima) was noninferior for overall survival while improving progression-free survival compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma.